Our Product Pipeline
We strive to provide the highest-quality reagents in support of infectious disease research. Some highlights of our current pipeline are shown below, but if you can’t see what you’re looking for, please contact us to find out if we already have it in development. If we don’t have what you need we may be able to develop it for you! For all coronavirus products, please see our Coronavirus Pipeline page.
Our antigen pipeline reflects our specialism in the manufacture of infectious disease antigens to ensure retention of their native configuration. From initial research through to scale-up production, we are focused on providing antigens that deliver real improvements to the sensitivity and specificity of serology-based IVDs, serve as effective immunogens and facilitate vaccine research and development. We specialise in preparing recombinant proteins using our in-house HEK293 mammalian cell expression system, which provides native post-translational modifications and correct folding. However, where appropriate, we also utilise E. coli and baculovirus-insect cell production systems. Our current R&D pipeline includes:
Design and Cloning
Undertaking an in silico review to design the optimal protein sequence and clone the sequence construct(s) into our optimised vectors.
Testing expression of a range of constructs in different platform systems to select the optimal conditions for this specific protein.
Purification and Scale-Up
Following expression we determine the best purification methods to maximise purity and yield, before scaling up to manufacturing quantities.
- Marburg Virus-Like Particle
- Influenza NA
- Varicella Zoster Virus gE/gI
- Human T-Lymphotrophic Virus 1 Envelope Protein
Our antibody pipeline reflects the continuing importance of developing highly specific, well-characterised antibodies for infectious disease research and diagnosis. In particular, understanding the cross-reactivity profile of antibodies within closely related virus families is of especial importance. Our antibodies are developed against mammalian-expressed antigens, which are properly glycosylated and therefore representative of the native antigen that the antibodies must bind to. Our current antibody pipeline includes the following targets:
Antigens are selected and immunisation strategies are designed to maximise a specific and non-cross-reactive response.
Screening and Selection
Screening for reactivity to the target antigen and careful selection of antibodies that show desired cross-reactivity profiles using extensive antigen range.
Expansion and Characterisation
Preparation of larger quantities of antibodies for further characterisation in a range of applications, including functional analyses where possible.
- Lassa Fever virus antibodies
- Alphavirus (Chikungunya, Mayaro and O’nyong’nyong) antibodies
- Severe Fever with Thrombocytopenia Virus antibodies
- Hepatitis E VLP antibodies
- Rift Valley Fever Virus Nucleoprotein antibodies